To close out Pulmonary Fibrosis Awareness month, our team came together for the 2026 PFF Walk, joining the community to raise awareness and funds for the Pulmonary Fibrosis Foundation. For us, the #PFFWalk is more than a shared experience. It reflects our collaborative, holistic approach to developing treatments that better meet the needs of people living with idiopathic pulmonary fibrosis (#IPF) and other fibrotic diseases. At Celea, we bring together scientific rigor, patient experience, clinical perspectives, and an understanding of the real-world challenges presented by IPF to inform how we develop medicines. We’re grateful to our team for walking together and supporting a new future for people with IPF. Our passion for the mission is what brings us together and keeps us moving forward. #PFMonth

Join us at #ERS2026! Celea will be presenting our SURPASS-IPF design (the first industry-sponsored, head-to-head, Phase 3 superiority trial in idiopathic pulmonary fibrosis #IPF) as well as key insights from a deupirfenidone drug-drug interaction study. These presentations reinforce deupirfenidone’s potential to serve as a new standard of care for the treatment of IPF. Find us at Booth H.02! bit.ly/3Se5ziG